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Abstract
Background: Although the soluble form of suppression of tumorigenicity 2 (sST2) and soluble low-density lipoprotein
receptor relative with 11 ligand-binding repeats (sLR11) have emerged as novel cardiovascular biomarkers in patients
with cardiovascular disease, their prognostic value has not been fully investigated in peritoneal dialysis (PD) patients.
Methods: We included 74 prevalent PD patients from a prospective cohort and measured serum sST2 and sLR11
concentrations by an enzyme-linked immunosorbent assay. The association of these biomarkers and all-cause mortality
and major adverse cardiac and cerebrovascular events (MACCEs) was evaluated.
Results: During a follow-up of 38.5 months, all-cause deaths and MACCEs were observed in 13 (17.6%) patients and 23
(31.3%) patients. Multivariable Cox analyses demonstrated that greater sST2 was independently associated with higher
risk of all-cause mortality (≥75.8 ng/mL; hazard ratio [HR] = 5.551; 95% confidence interval [CI] = 1.360–22.660) and
MACCEs (≥72.5 ng/mL; HR = 4.609; 95% CI = 1.608–13.208). Furthermore, sST2 showed additive predictive value for
mortality to the base model including traditional risk factors (net reclassification index = 0.598, P = 0.04). sLR11 was not
significantly associated with all-cause mortality or MACCE.
Conclusions: sST2, but not sLR11, indicated a significant prognostic value for all-cause mortality and cardiovascular
events in PD patients. Further research is needed to validate emerging biomarkers in these populations.
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Background
Although the survival rate of patients with chronic kidney
disease (CKD) has improved, cardiovascular disease re-
mains a major cause of mortality in this population [1]. In
CKD, cardiovascular changes are attributed to the kidney
disease itself or to dialysis treatment when CKD pro-
gresses to end-stage renal disease (ESRD) [1, 2]. Indeed,
approximately 20% or more of patients on dialysis develop
systolic or diastolic dysfunction, suggesting that cardiovas-
cular abnormalities are prevalent in ESRD patients [3].
Therefore, because predicting the risk of cardiovascular
disease is expected to play a crucial role in improving the
prognosis of cardiovascular disease, several studies have
addressed this issue by evaluating new biomarkers.
Suppression of tumorigenicity 2 (ST2) is a member of the
interleukin 1 receptor family, and its expression is stimu-
lated by myocardial stress and injury [4]. ST2 has two dif-
ferent forms: a cardio-protective transmembrane receptor
(ST2L) and a soluble decoy receptor (sST2) [5–7]. In con-
trast to ST2L, high concentrations of sST2 are associated
with cardiac fibrosis, myocardial hypertrophy and
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ventricular dysfunction [6–8]. Recent evidence has indi-
cated that sST2 is a useful prognostic marker, especially in
congestive heart failure [9, 10]. Low-density lipoprotein re-
ceptor relative with 11 ligand-binding repeats (LR11), a
member of the low-density lipoprotein receptor relatives, is
highly expressed in vascular smooth muscle cells exhibiting
enhanced migration, which leads to atherosclerosis [11–
15]. In addition to LR11, the soluble form of LR11 (sLR11)
also promotes vascular smooth muscle cell proliferation
and migration, suggesting that sLR11 levels reflect the de-
gree of vascular smooth muscle cell migration [14–21]. In
patients with coronary artery disease [18, 19], familial
hypercholesterolemia [21] and type 2 diabetes [16, 20],
sLR11 levels were found to be increased.
To date, the prognostic value of sST2 and sLR11 has
not been investigated in patients undergoing peritoneal
dialysis (PD). Only a few studies have evaluated the asso-
ciation between clinical outcomes and sST2 in non-
dialysis CKD patients and ESRD patients on haemodialy-
sis (HD) or haemodiafiltration [22–25] and there are no
studies that have focused on sLR11 in patients with kid-
ney diseases. Therefore, we assessed the association of
sST2 and sLR11 with adverse clinical outcomes in PD
patients. Moreover, we compared the predictive value of
sST2 and sLR11 with high-sensitivity C-reactive protein
(hs-CRP) to test their clinical relevance as emerging car-
diovascular biomarkers in these populations.
Methods
Study participants
This study involved participants from a prospective ob-
servational cohort of prevalent PD patients that was de-
signed to investigate factors associated with
cardiovascular risk and mortality in the Yonsei Univer-
sity Health System (YUHS). The details of this cohort
were reported previously [26]. Among the 102 patients
initially enrolled, 5 participants who had insufficient
sample volumes for analysis, 7 participants who with-
drew before additional blood analysis and 21 participants
who declined to store their blood samples were ex-
cluded. Finally, 74 participants were analyzed in this
study.
Collection of clinical and biochemical data
Clinical data, including age, sex, cause of ESRD, duration
of PD treatment, cardiovascular disease history, smoking
status, and medications, were collected at study enrol-
ment by a well-trained study coordinator. Smoking his-
tory was collected using a questionnaire. Smoking status
was categorized as never-smokers and ever-smokers.
Cause of ESRD, duration of PD treatment, comorbid dis-
eases, and medications were collected by careful chart
review. Cardiovascular disease was defined as coronary
artery disease, peripheral artery disease, or
cerebrovascular disease. Coronary artery disease was de-
fined as an acute coronary syndrome or angina requiring
coronary artery angioplasty or coronary artery bypass.
Peripheral artery disease was defined as ischaemic limb
loss and/or ulceration requiring peripheral artery revas-
cularization. Cerebrovascular disease was defined as a
transient ischaemic attack, cerebral infarction or carotid
endarterectomy. Diabetes mellitus was defined as a his-
tory of diagnosis or taking oral hypoglycaemic agents or
insulin treatment. Anthropometric measures and blood
pressure were determined by a single skilled nurse from
our PD unit in the morning after complete overnight di-
alysate emptying. Height and weight were measured and
body mass index was calculated. Blood pressure was
measured using a validated automatic oscillometric de-
vice. The average value of two measures was recorded.
To alleviate the variability from overnight peritoneal di-
alysate, overnight dialysate was not changed. Overnight
fasting blood (12-h) was collected at the time of study
enrolment and biochemical variables were measured in
the YUHS laboratory. For storing blood samples, an add-
itional 10 mL of whole blood was collected, and the ali-
quots of serum and plasma were stored in a deep freezer
at − 70 °C. Kt/V urea was calculated by PD Adequest 2.0
for Windows software (Baxter Healthcare, Deerfield, IL,
USA) for the assessment of dialysis adequacy.
Assessment of sST2, sLR11, and hs-CRP concentrations
Using stored samples, serum sST2, and sLR11 concen-
trations were measured by a colourimetric enzyme-
linked immunosorbent assay (ELISA; sST2, Presage® ST2
Assay, Critical Diagnostics, San Diego, CA, USA; sLR11,
MBS-167426, MyBioSource, San Diego, CA, USA). Inter-
and intra-assay coefficients of variation were both < 10%
for sST2, and < 15, and < 10%, respectively, for sLR11.
hs-CRP concentrations were measured by a BNII ana-
lyser (Dade Behring, Newark, DE, USA) using a latex-
enhanced immunonephelometric method.
Follow-up and study outcomes
Patients were followed every 3months at the PD unit of
the YUHS through September 2018. All adverse clinical
events, including deaths and hospitalizations, were re-
corded in the database of our PD unit. The primary out-
come was all-cause mortality and the secondary
outcome was a major adverse cardiac and cerebrovascu-
lar event (MACCE). Death or hospitalization from an
acute coronary syndrome, stable angina performing cor-
onary revascularization procedures, newly developed
congestive heart failure or cerebrovascular events was
defined as MACCE. Patients who did not experience pri-
mary outcome were censored at the end of the study
date and those who were lost to follow-up were cen-
sored at the date of the last examination. If patients
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underwent a kidney allograft or changed dialysis modal-
ity to HD, they were censored at the date of the last PD
treatment. If death occurred within 2 months after trans-
fer to HD, the death was considered as a death from PD.
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows version 20.0 (IBM Corp., Armonk, NY, USA) and
R software (R Foundation for Statistical Computing,
Vienna, Austria; www.r-project.org). Continuous vari-
ables are expressed as the mean ± standard deviation
(SD) or the median (interquartile range) and categorical
variables are expressed as the raw number (percentage).
To evaluate the association of sST2 and sLR11 with
study outcomes, study participants were dichotomized
based on the median values of each marker. The cut-off
value for sST2 and sLR11 was also calculated from re-
ceiver operating characteristic (ROC) analyses with the
calculated area under the ROC curve (AUC) in accord-
ance with previous studies [23, 24]. The value showing
the highest sensitivity was determined as the cut-off.
The calculated cut-off values of sST2 for all-cause mor-
tality and MACCEs were 75.8 ng/mL (sensitivity, 69.2%;
specificity, 60.7%) and 72.5 ng/mL (sensitivity, 65.2%;
specificity, 58.8%). The calculated cut-off of sLR11 for
all-cause mortality and MACCEs was 14.9 ng/mL (61.5%
sensitivity and 44.3% specificity for all-cause mortality;
52.5% sensitivity and 41.2% specificity for MACCEs).
Cumulative survival curves were constructed using the
Kaplan–Meier method and between-group survival was
compared using the log-rank test. To determine the in-
dependent prognostic value of sST2 and sLR11 for all-
cause mortality and MACCEs, Cox proportional regres-
sion analyses were performed. A multivariable model
was constructed with significant variables from univari-
ate analyses: sex, age, diabetes mellitus, and cardiovascu-
lar disease. Subsequent multivariable analysis was
performed with additional variables that were known to
be associated with adverse clinical outcomes in PD pa-
tients: duration of PD, smoking status, body mass index,
and haemoglobin concentrations. Using a fractional
polynomial model, sST2 and sLR11 were also evaluated
as continuous variables. To compare the predictive value
of sST2, sLR11, and hs-CRP for all-cause mortality and
MACCEs, we evaluated the additive effects of each bio-
marker on the base model: model 1, base model + sST2;
model 2, base model + sLR11; model 3, base model +
hs-CRP. The continuous net reclassification index (NRI),
the integrated discrimination improvement (IDI) and c
Statistics were calculated to ascertain which biomarker
improved prediction of the primary outcome when
added to the base model. A P value of less than 0.05 was
considered to indicate statistical significance.
Results
Baseline characteristics of participants
The baseline characteristics of study participants are
shown in Table 1. The mean age of patients was 53.9 ±
11.8 years, and 47 patients (63.5%) were men. The me-
dian PD duration was 30.0 (16.0–96.0) months. A total
of 21 patients (28.4%) were diabetic and 10 patients
(13.5%) had a history of cardiovascular disease. Diabetic
kidney disease was the most common cause of ESRD,
followed by hypertensive nephrosclerosis and glomerulo-
nephritis. The mean concentrations of serum sST2 and
sLR11 were 75.0 ± 26.6 ng/mL and 16.4 ± 4.8 ng/mL, re-
spectively, the median value of hs-CRP was 0.96 (0.62–
2.10) mg/L.
Prognostic value of sST2 for all-cause mortality and
MACCE
During a median follow-up of 38.5 months, 13 (17.6%)
patients died and there were 23 (31.3%) MACCEs. When
patients were dichotomized based on the median value
of sST2 (70.9 ng/mL), crude all-cause death rates were
1.74 and 10.18 per 100 person-years, and MACCE rates
were 6.15 and 13.47 per 100 person-years in the low and
high sST2 groups, respectively (Table S1). The cumula-
tive survival rate was significantly lower in the high sST2
group (log-rank test; P = 0.002 for all-cause mortality
and P = 0.01 for MACCEs) (Fig. 1). In multivariable Cox
regression analysis, the high sST2 (above the median)
was significantly associated with increased risk for all-
cause mortality and MACCEs (Table 2). When patients
were categorized using calculated cut-off values of sST2,
the high sST2 group had a 5.551- and 4.609-fold in-
creased risk for all-cause mortality and MACCEs com-
pared to the lower sST2 group. Moreover, the
prognostic value of sST2 remained significant as a con-
tinuous variable (per 1 SD increase, hazard ratio [HR] =
1.943; 95% confidence interval [CI] = 1.124–3.359 for all-
cause mortality and HR = 1.630; 95% CI = 1.073–2.477
for MACCEs). When dialysis adequacy was added to
multivariable models, the prognostic value of sST2
remained consistent (Table S2). Multivariable fractional
polynomial analysis indicated that the risk of all-cause
mortality and MACCEs increased steadily with higher
sST2 levels, showing a linear relationship (Fig. 2).
Prognostic value of sLR11 for all-cause mortality and
MACCEs
Patients were dichotomized based on the median value
of sLR11 (15.2 ng/mL). All-cause death rates were 5.34
and 4.12 per 100 person-years, and MACCE rates were
9.78 and 7.76 per 100 person-years in the low and high
sLR11 groups, respectively (Table S1). There were no
differences in all-cause death or MACCE-free survival
rates between the high and low sLR11 groups (both P >
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0.05) (Fig. 1). Multivariable Cox regression analysis
showed there was no significant association between
sLR11 and all-cause mortality or MACCEs, regardless of
using median value (15.2 ng/mL) or calculated cut-off
(14.9 ng/mL) (Table 2). Fractional polynomial analysis
indicated a non-linear relationship (Fig. 2).
Predictive value of sST2, sLR11, and hs-CRP for all-cause
mortality and MACCE
The predictive value of sST2, sLR11, and hs-CRP was
evaluated using ROC analysis (Fig. 3), continuous NRI,
IDI, and c Statistics (Table 3). The AUCs of sST2 for all-
cause mortality and MACCEs were 0.699 (P = 0.03) and
0.644 (P = 0.04), respectively. In contrast, the AUC of
sLR11 and hs-CRP were not significant. Furthermore,
when sST2 was added to the base model that included
traditional risk factors (model 1), only sST2 significantly
improved the predictive ability of all-cause mortality
(NRI = 0.598, P = 0.04). However, sLR11 (model 2) or hs-
CRP (model 3) did not increase predictability for all-
cause mortality. In terms of MACCE, there was no sig-
nificant advantage from adding sST2, sLR11, or hs-CRP
to the base model. Similar to IDI, the ability of discrim-
ination was not significant in c Statistics.
Discussion
In the present study, we first demonstrated that higher
sST2 concentrations are independently associated with a
greater risk of all-cause mortality and MACCEs in
prevalent PD patients. In contrast, we did not find a sig-
nificant association between sLR11 and study outcomes.
Only sST2 improved the predictive ability of all-cause
mortality, when added to the base model including trad-
itional risk factors.
Previous studies indicated that ST2L, the transmem-
brane receptor form of ST2, exhibited cardio-protective
effects associated with binding to interleukin-33 (IL-33),
which results in a reduction in cardiomyocyte apoptosis
and fibrosis or hypertrophy of injured cardiac tissues [4,
5]. The soluble form of ST2, sST2, is a decoy receptor
[6, 7]. As its concentration increases, sST2 competitively
binds to IL-33 and disrupts the ST2L/IL-33 interaction,
thus inhibiting cardio-protective signalling [6, 7]. There-
fore, the sST2 level has been widely investigated as a
biomarker of cardiovascular disease, especially in pa-
tients with congestive heart failure [8–10]. Two recent
meta-analyses demonstrate clearly that sST2 has a sig-
nificant prognostic value in heart failure patients [9, 10].
In chronic heart failure, sST2 also showed a significant
prognostic value for all-cause and cardiovascular mortality
[9]. A study of acute congestive heart failure found that
higher sST2 concentrations at both admission and dis-
charge are significantly associated with all-cause and car-
diovascular mortality or hospitalization due to heart
failure [10]. Furthermore, repeated measurements of sST2
concentration are useful for assessing the clinical course
of heart failure, suggesting that sST2 is a suitable bio-
marker for disease monitoring as well as prognosis [27].
Only a few studies have investigated the prognostic
value of sST2 in patients with kidney diseases. One study
involving 883 pre-dialysis CKD patients showed that
Table 1 Baseline characteristics of study participants
N = 74
Age (years) 53.9 ± 11.8
Male, n (%) 47 (63.5)
Duration of PD (months) 30.0 (16.0–96.0)
Cases of ESRD, n (%)
Diabetic kidney disease 21 (28.4%)
Hypertensive nephrosclerosis 19 (25.7%)
Glomerulonephritis 17 (23.0%)
Polycystic kidney disease 3 (4.1%)
aOthers 3 (4.1%)
Unknown 11 (14.9%)
Diabetes mellitus, n (%) 21 (28.4)
Cardiovascular disease, n (%) 10 (13.5)
Ever-smokers, n (%) 29 (39.2)
Lipid-lowering therapy, n (%) 28 (37.8)
Systolic blood pressure (mmHg) 133.7 ± 21.5
Diastolic blood pressure (mmHg) 75.0 ± 11.6
Body mass index (kg/m2) 23.1 ± 2.8
Hemoglobin (g/L) 104 ± 11
Glucose (mmol/L) 5.3 ± 2.4
Blood urea nitrogen (mmol/L) 7.4 ± 2.1
Creatinine (μmol/L) 972.4 ± 371.3
Albumin (g/L) 35 ± 5
Triglyceride (mmol/L) 1.3 ± 0.8
Total cholesterol (mmol/L) 4.3 ± 0.9
LDL cholesterol (mmol/L) 2.4 ± 0.7
HDL cholesterol (mmol/L) 1.1 ± 0.3
Calcium (mmol/L) 2.2 ± 0.2
Phosphorous (mmol/L) 1.7 ± 0.5
Total Kt/V urea (per week) 2.1 ± 0.4
nPCR (g/kg/day) 0.97 ± 0.17
hs-CRP (mg/L) 0.96 (0.62–2.10)
sST2 (ng/mL) 75.0 ± 26.6
sLR11 (ng/mL) 16.4 ± 4.8
Data are expressed as mean ± standard deviation, median (interquartile range),
or number of patients (percent)
Abbreviations: hs-CRP high-sensitivity C-reactive protein, HDL high-density
lipoprotein, Kt/V urea fractional urea clearance, LDL low-density lipoprotein,
nPCR normalized protein catabolic rate, PD peritoneal dialysis, sLR11 soluble
form of low-density lipoprotein receptor relative with 11 ligand-binding
repeats, sST2 soluble form of suppression of tumorigenicity 2
aOthers: interstitial nephritis, obstructive uropathy, or post status
of nephrectomy
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higher sST2 concentrations are associated with increased
mortality risk [25]. In a subgroup analysis of heart failure
patients, high sST2 level remained a significant prognos-
tic factor in patients with an estimated glomerular filtra-
tion rate < 60 mL/min/1.73 m2 [28]. In HD patients, two
studies reported that sST2 had a significant association
with all-cause mortality [23] and cardiovascular events
[24]. In the current study, we revealed for the first time
that prevalent PD patients with elevated sST2 levels have
a greater risk of all-cause mortality and MACCEs. The
significant prognostic value of sST2 remained unaltered
when patients were categorized using both median value
and calculated cut-off. To date, there is no definite sST2
cut-off for the prediction of clinical outcomes in popula-
tions with kidney diseases. Previous HD studies suggested
a 48 ng/mL for all-cause mortality [23] or 58 ng/mL for
MACCE [24], respectively. In this study, the calculated
cut-off for sST2 was 75.8 ng/mL for all-cause mortality
and 72.5 ng/mL for MACCE, which were higher than
those of previous studies. In prevalent HD patients in
Slovenia, the median value of sST2 was 28 ng/mL [23]. In
a study of Korean incident HD patients, the median value
of sST2 was 59.5 ng/mL [24]. Because our patients were
prevalent PD patients with a median dialysis vintage of 30
months, we assumed that our patients may be at higher
cardiovascular risk than incident dialysis patients, leading
Fig. 1 Kaplan-Meier plots for study outcomes for high and low sST2 and sLR11 groups. The high sST2 group had significantly greater risk of all-
cause death (a) and MACCEs (b) compared with the low sST2 group. There were no significant differences in the risk of all-cause death (c) and
MACCEs (d) between the high and low sLR11 groups. Abbreviations: MACCE, major adverse cardiac and cerebrovascular event; sLR11, soluble
form of low-density lipoprotein receptor relative with 11 ligand-binding repeats; sST2, soluble form of suppression of tumorigenicity 2
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to higher cut-off and median value of sST2. However, we
did not clarify the exact reason for the discrepancy in cut-
off and median values of sST2, such as ethnicity, dialysis
modality (HD or PD), or dialysis vintage. Future studies
are needed to address this issue.
In the present study, the AUCs of sST2 for all-cause
mortality and MACCE were significant and sST2 signifi-
cantly improved the predictive ability for all-cause mor-
tality when it was added to the base model that included
traditional risk factors. From these results, we surmised
that sST2 could be helpful in predicting adverse clinical
outcomes in PD patients. However, the absolute values
of the AUCs were not high (0.699 for all-cause mortality
and 0.644 for MACCE) and sST2 did not show additive
predictive value for MACCE compared with the base
model. The discrimination index was not significant.
These findings suggest that sST2 alone does not out-
weigh the predictive ability of traditional risk factors for
cardiovascular outcomes. Nevertheless, fractional poly-
nomial analyses found a linear association between sST2
concentrations and study outcome, which can be easily
interpreted in clinical practice. Moreover, the sST2 con-
centration is independent of kidney function and CKD
stage [28, 29] and not affected by haemodiafiltration
procedures [30]. Interpretation of serum concentrations
of biomarkers that are affected by kidney function or
dialysis is complex and thus not easily applicable to real-
world clinical settings. Based on these results, we specu-
late that sST2 can be a clinically relevant biomarker in
PD patients. However, further investigation with a larger
number of participants is necessary to evaluate the addi-
tive predictive value of sST2 for adverse cardiovascular
outcomes in a PD population.
Previous studies have reported that sLR11 is implicated
in coronary artery disease [18, 19], carotid atherosclerosis
[20] and vascular calcification [21]. However, to date,
sLR11 has not been investigated in patients with kidney
diseases, and this study revealed that sLR11 concentration
is not correlated with the risk of death or cardiovascular
disease in prevalent PD patients. The mechanism by
which LR11 mediates atherosclerosis reportedly involves
the enhancement of vascular smooth muscle cell prolifera-
tion and migration [11–15]. LR11 produced by intimal
smooth muscle cells induces increased smooth muscle cell
migration in vitro via the upregulation of urokinase-type
plasminogen activator receptor expression [15]. Of note,
postprandial triglyceride-rich lipoproteins stimulate LR11
release from aortic smooth muscle cells, and
Table 2 Multivariable Cox proportional hazard models of sST2 and sLR11 for all-cause mortality and MACCEs
Crude HR (95% CI) aAdjusted HR 1 (95% CI) bAdjusted HR 2 (95% CI)
All-cause mortality
sST2
csST2≥ 70.9 ng/mL (vs. < 70.9) 6.715 (1.749–25.784) 9.638 (2.180–42.602) 10.144 (2.156–47.734)
dsST2≥ cut-off (vs. <cut-off) 9.459 (2.034–43.988) 12.189 (2.408–61.696) 5.551 (1.360–22.660)
sST2 (per 1 SD increase) 2.179 (1.351–3.515) 1.921 (1.151–3.207) 1.943 (1.124–3.359)
sLR11
csLR11≥ 15.2 ng/mL (vs. < 15.2) 0.791 (0.258–2.422) 0.630 (0.187–2.130) 0.601 (0.168–2.145)
esLR11≥ cut-off (vs. <cut-off) 1.271 (0.415–3.896) 0.944 (0.271–3.286) 0.859 (0.211–3.503)
sLR11 (per 1 SD increase) 0.884 (0.503–1.555) 0.763 (0.397–1.467) 0.719 (0.356–1.451)
MACCEs
sST2
csST2≥ 70.9 ng/mL (vs. < 70.9) 2.056 (1.259–6.940) 4.623 (1.743–12.263) 3.928 (1.413–10.918)
dsST2≥ cut-off (vs. <cut-off) 3.776 (1.546–9.218) 5.445 (2.020–14.679) 4.609 (1.608–13.208)
sST2 (per 1 SD increase) 1.748 (1.179–2.592) 1.683 (1.120–2.529) 1.630 (1.073–2.477)
sLR11
csLR11≥ 15.2 ng/mL (vs. < 15.2) 0.743 (0.321–1.723) 0.736 (0.29301.849) 0.737 (0.271–2.002)
esLR11≥ cut-off (vs. <cut-off) 1.278 (0.551–2.965) 1.315 (0.532–3.250) 1.315 (0.487–3.548)
sLR11 (per 1 SD increase) 0.951 (0.634–1.428) 0.947 (0.606–1.481) 0.927 (0.577–1.490)
Abbreviations: CI confidence interval, HR hazard ratio, MACCE major adverse cardiac and cerebrovascular event, PD peritoneal dialysis, SD standard deviation, sLR11
soluble form of low-density lipoprotein receptor relative with 11 ligand-binding repeats, sST2 soluble form of suppression of tumorigenicity 2
aAdjusted HR 1 was calculated after adjustment of age, sex, diabetes mellitus, and history of cardiovascular disease
bAdjusted HR 2 was calculated after adjustment of age, sex, PD duration, diabetes mellitus, history of cardiovascular disease, smoking status, body mass index,
and hemoglobin concentrations
cPatients were dichotomized based on median values of sST2 (70.9 ng/mL) and sLR11 (15.2 ng/mL), respectively
dPatients were categorized into two groups based on the calculated cut-off of sST2 for all-cause mortality (75.8 ng/mL) and MACCEs (72.5 ng/mL)
ePatients were categorized into two groups based on the calculated cut-off of sLR11 (14.9 ng/mL) for all-cause mortality and MACCEs
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overexpression of LR11 increases binding of triglyceride-
rich lipoproteins but not low-density lipoprotein [31], sug-
gesting a close association with triglycerides. In CKD pa-
tients, non-traditional risk factors, such as uraemia,
inflammation, malnutrition or mineral-bone disease also
contribute to a high risk of developing cardiovascular dis-
ease, in addition to the traditional risk factors such as ad-
vanced age, smoking, diabetes, and dyslipidaemia [32]. In
this study, the mean triglyceride concentrations were 1.3
mmol/L, which is lower than the cut-off for hypertriglyc-
eridemia (> 2.3 mmol/L) in the general Korean population.
Triglyceride level was not a significant risk factor for mor-
tality or MACCEs in the univariate Cox analysis (data not
shown). Considered collectively, these data suggest that
the lower contribution of dyslipidaemia to the develop-
ment of cardiovascular disease in a CKD setting could ex-
plain the non-significant association between sLR11 levels
and prognosis in our patients. Furthermore, uraemia and
impaired kidney function can alter the expression or me-
tabolism of sLR11 in patients with kidney diseases, and
dialysis procedures can also affect sLR11 concentrations.
However, there are no available data on sLR11 concentra-
tions in ESRD patients, thus further studies are needed to
clarify this issue.
This study has several limitations. First, the number of
study participants was small, resulting in a small number
of primary outcomes. Although our multivariable
models were well fitted (Table S3), the potential risk of
overfitting still exists. In addition, we cannot exclude
type II errors for the non-significant prognostic value of
sLR11. To mitigate these confounding effects, a frac-
tional polynomial analysis was performed to explore the
association of sST2 and sLR11 with primary outcome
using continuous terms. In the fractional polynomial
Fig. 2 Multivariable fractional polynomial graph for association of sST2 and sLR11 with study outcomes. Hazard ratios were calculated after
adjustment for age, sex, peritoneal dialysis duration, diabetes mellitus, history of cardiovascular disease, smoking status, body mass index, and
hemoglobin for all-cause death and MACCE. sST2 indicated a linear relationship with the risk of (a) all-cause mortality and (b) MACCEs. sLR11 did
not show a remarkable trend with (c) all-cause mortality and (d) MACCEs. Shaded areas indicate 95% confidence intervals. Abbreviations: MACCE,
major adverse cardiac and cerebrovascular event; sLR11, soluble form of low-density lipoprotein receptor relative with 11 ligand-binding repeats;
sST2, soluble form of suppression of tumorigenicity 2
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analysis, sST2 showed a linear relationship but sLR11
showed a non-linear relationship with study outcomes.
Therefore, even if our study was underpowered to detect
a significant difference, the clinical utility of sLR11 as a
biomarker is low due to the complexity of its interpret-
ation, at least in PD patients. However, our findings
should be interpreted with caution and should be con-
firmed by external validation in another independent co-
hort. Furthermore, a large-scale prospective investigation
is mandatory to confirm our results. Second, this study
analyzed only Korean prevalent PD patients. We have
presumed that our participants were at high risk of car-
diovascular disease due to a relatively long duration of
PD. However, on the contrary, our participants have
been tolerable to PD treatment until study enrolment.
Given the high mortality risk in the early period of dialy-
sis commencement, investigating prevalent PD patients
may lead to a survival bias. Third, in the current study,
Fig. 3 Receiver operating characteristic curves for sST2, sLR11, and hs-CRP to predict all-cause mortality and MACCEs. sST2 exhibited a significant
predictive value for (a) all-cause mortality and (b) MACCEs (both P < 0.05). Abbreviations: hs-CRP, high-sensitivity C-reactive protein; MACCE, major
adverse cardiac and cerebrovascular event; sLR11, soluble form of low-density lipoprotein receptor relative with 11 ligand-binding repeats; sST2,
soluble form of suppression of tumorigenicity 2
Table 3 NRIs, IDIs, and c Statistics for prediction of all-cause mortality and MACCE
Models NRI aP IDI aP c Statistics aP
(95% CI) (95% CI)
All-cause mortality
Base model Reference Reference 0.729
Model 1 0.598 (0.039 to 1.156) 0.04 0.029 (− 0.0068 to 0.0655) 0.11 0.863 0.48
Model 2 0.225 (− 0.372 to 0.821) 0.46 0.005 (−0.014 to 0.024) 0.61 0.731 0.19
Model 3 0.477 (−0.106 to 1.059) 0.11 0.027 (−0.0005 to 0.060) 0.10 0.765 0.71
MACCE
Base model Reference Reference 0.718
Model 1 0.385 (−0.099 to 0.870) 0.12 0.008 (−0.014 to 0.030) 0.49 0.801 0.46
Model 2 0.133 (−0.357 to 0.627) 0.59 0.019 (−0.013 to 0.050) 0.24 0.705 0.33
Model 3 0.007 (−0.481 to 0.495) 0.9 0.001 (−0.002 to 0.007) 0.82 0.720 0.47
Base model: adjusted for age, sex, PD duration, smoking, diabetes mellitus, cardiovascular disease, body mass index, and hemoglobin
Model 1: base model + sST2
Model 2: base model + sLR11
Model 3: base model + hs-CRP
Abbreviations: CI confidence interval, IDI integrated discrimination improvement, hs-CRP high-sensitivity C-reactive protein, PD peritoneal dialysis, MACCE major
adverse cardiac and cerebrovascular event, NRI net reclassification index, sLR11 soluble form of low-density lipoprotein receptor relative with 11 ligand-binding
repeats, sST2 soluble form of suppression of tumorigenicity 2
avs. Base model
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the proportion of participants who had diabetes mellitus
was 28.4%, which is lower than the 50.2% of Korean dia-
lysis patients [33]. Moreover, only 13.5% of the partici-
pants had a history of cardiovascular disease. These
findings suggest that our study participants were more
likely to be in a better clinical condition compared with
other PD cohorts, introducing a selection bias. Further-
more, several patients were excluded from the original
cohort due to lack of blood samples or withdrawal from
further study participation, leading to the potential for
another selection bias. To abrogate the effect of selection
bias, we analyzed differences in baseline characteristics
between patients with and without biomarker measure-
ments. We found no significant differences in baseline
characteristics except for PD duration and haemoglobin
between patients who had available sST2 and sLR11
concentration measurements and those who did not
(Table S4). Nevertheless, 74 patients may not be repre-
sentative of all participants in our original cohort.
Fourth, this study included a small number of partici-
pants from a single tertiary hospital in Korea. Because
there are huge differences in medical resources and dia-
lysis practice pattern among institutions, our results may
not be generalized to other populations. Fifth, due to the
observational nature of this study, we cannot evaluate
the causal relationship between sST2 or sLR11 and the
development of our primary outcome. Although we sur-
mised that a significant association of sST2 with cardiac
fibrosis, myocardial hypertrophy, or ventricular dysfunc-
tion observed in previous studies may contribute to the
prognostic value of sST2 on mortality and MACCEs,
underlying mechanisms were not investigated in this
study. Furthermore, the effects of changes in sST2 and
sLR11 on mortality or cardiovascular disease were not
evaluated, exerting an unmeasured confounding effect.
Although multivariable Cox models were constructed
with significant variables from univariate analysis and
additional variables which were known to be associ-
ated with adverse clinical outcome in PD patients,
we cannot totally exclude residual confounding ef-
fects derived from the observational study. Sixth, be-
cause there is no definite cut-off for sST2 and sLR11
in patients with kidney diseases, we calculated the
cut-off value using ROC analysis. These cut-offs need
to be validated in further studies. Lastly, we only de-
termined concentrations of sST2 and sLR11 and did
not evaluate other emerging cardiovascular bio-
markers, such as growth differentiation factor 15 or
galectin 3. Determining and comparing the prognos-
tic value of various new biomarkers is worthwhile.
Despite these limitations, we believe that the current
study provides useful information regarding the prog-
nostic value of emerging cardiovascular biomarkers
in PD patients.
Conclusions
The present study reveals that sST2 is a significant prog-
nostic factor in PD patients. However, we found no sig-
nificant association between SLR11 and the study
outcomes. These findings suggest that sST2 may be a
useful biomarker for stratifying mortality and cardiovas-
cular risk in patients undergoing PD. However, add-
itional studies to validate these emerging cardiovascular
biomarkers in this population are needed.
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